macroeconomics and health, WHO commission 82:957–958
macular degeneration, global data for 2002 82:844–851
Madagascar
autodisable syringes for national immunization programme 81:553–560
flood-related problems 78:562
regulating contracting practices 84:897–902
Madness: a brief history (Porter) 80:603
magnesium sulfate, for pre-eclampsia and eclampsia in Mexico and Thailand 85:763–767
Magnivisualizer, for cervical cancer screening 78:964–967
Making medicines affordable (Chaudhury & Gurbani) 84:424
Making Pregnancy Safer (MPS) initiative, in Uganda 84:847–849
malaria
averting a disaster in Africa 82:381–384
chemoprophylaxis
in children: effects on haematological responses, morbidity and mortality 81:205–216
in infants 78:97–107
in pregnancy in Mozambique 85:873–879
re-emergent Plasmodium vivax, in Republic of Korea 84:827–834
child mortality
in Africa 81:472
malnutrition underlying 78:1207–1221
childhood
burden of anaemia in Tanzania 81:581–590
in complex emergencies 84:58–64
climate change and 78:1136–1147, 80:334–335
in complex emergencies 78:1062, 84:58–64
continuing medical education 77:948
control
aircraft disinsection 78:995–1004
cost in China 80:653–659
cost in Sri Lanka 77:301–309
DDT for 79:79, 82:472–473
economics of international aid 82:554–555
geographical information systems 78:1401–1411, 78:1438–1444
global resources needed to attain goals 85:623–630
house spraying and insecticide-treated nets 78:1389–1400, 79:77, 79:687
insecticide-treated nets see insecticide-treated nets
need for global initiatives 79:869–874
in pregnancy in Mozambique 85:873–879
prospects 78:1376, 78:1377, 78:1450–1455
spatial targeting of interventions 78:1401–1411
sponging livestock with insecticide 79:797
in Viet Nam 80:660–666
WHO's role 83:168–170
in Zimbabwe 77:295–296
see also Roll Back Malaria
deaths/mortality
confidential enquiry 77:263–266, 77:1020
counting in Rwanda 85:251–252
estimating 84:165–166
in Kenya 80:919
and morbidity in Africa 77:617–618, 77:624–640
in Myanmar 77:310–314
diagnosis
case definitions in Bangladesh 79:648–656
febrile children in low prevalence area 79:1096–1105
in remote areas 79:933–941
drugs see antimalarial drugs
El Niño and 78:1127–1135
elimination, in Eastern Mediterranean Region 85:507–508
endemicity, child mortality and 79:375–376
falciparum see under Plasmodium falciparum
global fund to fight see Global Fund to Fight AIDS Tuberculosis and Malaria
haemoglobin variant protecting against 80:78–79
imported (1985–95) 77:560–566
knowledge systems approach 84:629–635
monkey, spread to humans 82:392–393
parasites
drug resistance 78:1378–1388, 78:1477
legacy of Ronald Ross 85:894–896
life cycle 79:174
Malarone resistance 81:382–383
sporozoites 78:1445–1449
tests of chloroquine resistance 77:34–43
see also Plasmodium falciparum
in pregnancy
adverse birth outcomes and, in Tanzania 85:9–18
in India 77:567–572
rapid assessment in Kenya 81:316–323
susceptibility of pregnant women 78:1370–1371
treatment 78:274
rates in Amazon region of Brazil 79:1171
research
funding 78:1054–1061, 79:581
post-genomic era 78:1424–1437
role of social science research 80:251–252, 80:683
systematic reviews and knowledge translation 84:643–651
treatment
artemisinin combination therapy see artemisinin combination therapy
combination therapy in Africa 78:1378–1388
criticisms of WHO policy 82:237
febrile children in low prevalence area 79:1096–1105
health-seeking behaviour in Tanzania 78:1352–1357
home-based, in Uganda 84:771–772
Malarone Donation Programme 80:817–821
in pregnancy 78:274
self-, in rural Ethiopia 81:261–268
willingness to pay for, in Tanzania 83:845–852
see also antimalarial drugs
vaccines
global partnerships 78:407
progress with new 81:902–909
vectors
molecular entomology 78:1412–1423

*see also* mosquitoes

*Malaria in pregnancy* (Duffy & Fried) 80:418
Malaria Network web site 77:706

Malarone
Donation Programme for malaria control 80:817–821
resistance, *Plasmodium falciparum* 81:382–383

malathion
carboxylesterase mechanism, in mosquitoes 79:1060–1064
resistance, in mosquitoes 79:1060–1064

Malawi
antiretroviral therapy outcomes for "lost to follow-up" patients 85:550–554
assessing prevalence of trachoma 81:877–885
breastfeeding and health of HIV-positive mothers 84:546–554
contribution to "3 by 5" antiretroviral therapy initiative 85:156–160
cotrimoxazole prophylaxis in HIV-positive tuberculosis 82:354–363
ensuring uninterrupted supply of antiretroviral drugs 85:152–155
essential medicines for chronic diseases 85:279–288
estimating coverage of selective feeding programmes 83:20–26
evolving humanitarian crisis 83:807–808
human resources impact of antiretroviral therapy scale-up 85:851–857
impact of tobacco control 79:480, 79:1086
joint tuberculosis/HIV services 85:385–386
nationwide scale-up of antiretroviral therapy 84:320–326
patient and household costs of tuberculosis diagnosis 85:580–585
provision of clean drinking water to refugees 79:280–287
pulmonary tuberculosis defaulters 77:386–391
triage and emergency care for children 84:314–319
tuberculosis prevention among health workers 80:526–531

Malaysia
health imperatives in foreign policy 85:225–229
monkey malaria in humans 82:392–393
reducing maternal mortality 77:190–193
*Vi* polysaccharide typhoid vaccine 79:811–817

Mali
female genital mutilation 82:153–154
HIV testing in population-based survey 84:537–545
integration of basic dermatological care into primary health care services 83:935–941
polio cases 82:717
syndromic management of vaginal discharge 84:729–738
treatment of epilepsy with phenobarbital 80:532–537
tuberculosis control using DOTS 85:402–403

malnutrition
analysis of trends 78:1222–1233
child mortality and 78:1271–1280
in complex emergencies 84:58–64
composite index of anthropometric failure 84:335
geographical distribution in Africa 83:764–770
implementation of WHO guidelines in African hospitals 81:237–243
inadequate weight gain in Brazil 77:895–905
kwashiorkor 81:910–911, 81:912–913
measurement in India 83:210–216
mortality in post-war Angola 81:849–850
and poverty, global data 83:118–126
protein–energy, and sugar intake 81:599–608
in southern Africa 80:764
supplementary feeding, in Guatemala 80:926–932
underlying deaths from infectious diseases 78:1207–1221
see also nutrition; nutritional status; underweight
managed care 79:755–763
US experience 78:830–844
management of health services
in Lao People's Democratic Republic 84:132–138
translating knowledge and building a learning organization 84:652–657
Management of the child with a serious infection or severe malnutrition (WHO 2002) 81:854
managers (health care)
    coping strategies of underpaid 80:581–584
    information systems for 83:637
Mandela, Nelson 78:1169
manic-depressive disorder see bipolar disorder
Manitoba Injury Outcome Study 84:802–810
Manual of basic techniques for a health laboratory, 2nd edition (WHO) 82:229
Marijuana and madness (Castle & Murray) 83:479
marital status, family-planning service provision and, in China 82:274–280
Marmot, Professor Sir Michael, interview 84:267–84:268
marriage, condom use within 82:180–186, 83:239
mass campaigns
    drug administration programmes in Nigeria 84:673–676
    vs general health services 83:315–316, 83:317–319
maternal and newborn health services
    assessment in developing countries 80:721–727
    focus on improving newborn care 81:224–225
    global resources needed to attain universal coverage 85:256–263
    poor–rich inequalities in developing countries 85:745–754
    in rural communities 80:759–760
    strengthening national plans 85:577–579
World health report 2005 84:327–332
see also child health services; maternal health services; obstetric services
maternal deaths see maternal mortality
maternal health
    equity-sensitive monitoring of Millennium Development Goals 84:519–527
    impact of breastfeeding by HIV-positive mothers 84:546–554
    WHO's role in promoting 83:247–248
    World health report 2005 83:402, 84:327–332
maternal health services
    indicators of need 80:317–324
    inequalities in use in developing countries 85:812–819
    preventing HIV transmission, in Democratic Republic of Congo 84:969–975
    private sector, in low- and middle-income countries 81:616–623
    reviews of maternal deaths in Senegal 84:218–224
    strategies for delivery in Bangladesh 79:142–149
maternal morbidity, from direct obstetric causes 78:593–602
maternal mortality
abortion 78:580–592
aetiology in developing countries 79:805–810
assessment in Argentina 85:615–622
confidential enquiries, in developing countries 85:68–69
direct obstetric causes 78:593–602
district-based audit in Indonesia 80:228–234
estimates in Ghana 79:400–408
in Indonesia 85:740–741
infant and child mortality risk and, in rural Burkina Faso 82:265–273
infant mortality risk and, in Nepal 81:717–725
knowledge gaps in scientific literature 84:903–909
measurement in developing world 84:173–180
measurement using census data 79:657–664
models of obstetric care and 77:399–406
monitoring in Tanzania 81:87–94
need for research 83:86–87
new WHO initiative 82:810
risk in rural Nepal 80:887–891
in rural Gambia 78:603–613
in Russian Federation 84:283–289
in Senegal, effects of facility-based reviews of maternal deaths 84:218–224
strategy for reducing 77:190–193
trends in 1990s 79:561–568
usefulness of estimating 79:179, 79:900
maternity services see maternal and newborn health services
MDGs see Millennium Development Goals
measles
in complex emergencies 84:58–64
deaths
malnutrition underlying childhood 78:1207–1221
reduction in global 82:394
diagnosis
laboratory, in low-transmission settings 82:852–857
oral fluid for 80:76–77
reliability of criteria 78:861
eradication
prospect for global 79:584–585, 82:134–138
vaccination strategies 78:949
immunity
antibody assay using dried venous blood samples 81:701–707
antibody profiles and immunization policies 79:615–624
in Italy 78:950–955
oral fluid samples for evaluating 79:588–595
outbreaks
in Europe 82:889–890, 82:889
response immunization 77:545–552
surveillance
vaccination
- in Australia 84:105–111
- oral fluid for 80:76–77
- in African Region 85:449–457
- in Burkina Faso 79:296–300
- campaign in Kenya 80:989
- children at risk of HIV infection 81:61–70
- computerized database for monitoring safety, in Viet Nam 83:604–610
- distributing insecticide-treated bednets during 83:195–201
- effect on child mortality in rural India 81:244–250
- in Hong Kong SAR 80:585–591
- impact of HIV pandemic 83:329–337
- non-specific effects on mortality 83:238
- strategies for elimination 78:949
- two-dose programme 77:132–137

vaccine
effectiveness, and risk factors for measles in Bangladesh 80:776–782
- immune response 79:1038–1046
- and measles–rubella vaccine, aerosolized vs injected 80:806–812
- non-specific effects on child mortality 81:821–826
- review of evidence on safety 78:199–204
- risk of adverse events 78:224–231

measles-mumps-rubella vaccine (MMR)
- economic analyses 80:264–270
- review of evidence on safety 78:199–204

mebendazole
- for intestinal nematode infections in Zanzibar 81:343–352
- mass treatment in Brazil 82:563–571

Médecins Sans Frontières (MSF), Drugs for Neglected Diseases initiative (DNDi) 80:842–843

media
groups, Global Media AIDS Initiative 82:232–233
- on SV40 in poliovirus vaccines 78:195–198
- on vaccine safety 78:216–218

medical assistants, training for surgery 77:688–691

medical education
- clinical pharmacology 77:707
- continuing (CME)
  - in India 82:154–155
  - in unstable malaria areas 77:948
- on food safety in prevention of infant diarrhoea 81:842–843
- on musculoskeletal disorders 81:677–683
- in North America, Flexner report 80:592–593, 80:594–602
- see also public health education

Medical ethics manual (Williams) 84:159–160

medical informatics, in developing countries 79:850–855

The Medical profession and human rights: handbook for a changing agenda (British Medical Association) 79:997

medicinal plants
- use by indigenous communities in Bolivia 82:243–250
- see also herbal medicines
medicines

- advance price or purchase commitments 83:301–307
- availability
  - benchmarking intellectual property 84:366–370
  - cheapness limiting 78:146
  - in developing countries 79:176
  - implications of bilateral free trade agreements 84:399–404
- costs using IMCI guidelines, in rural Kenya 77:852–858
- counterfeit see counterfeit medicines
- development see drug development
- donations by USA 77:675–680
- environmental health impact 81:768–769
- essential see essential medicines
- EU measures to prevent diversion of low-price 81:549
- fixed-dose combinations
  - antimalarial drugs 79:394–399
  - antituberculous agents 79:61–68
  - polypill for chronic disease 83:885–887
  - vs unit-of-use packaging 82:935–939
- generic see generic drugs
- intellectual property rights 79:381, 79:461–470
- International Pharmacopoeia (WHO) 81:311
- mass administration programmes in Nigeria 84:673–676
- for neglected and emerging infectious diseases 85:572
- orphan see orphan drugs
- policies in 10 Latin American countries 83:64–70
- Priority Medicines Project 83:324
- revolving funds 77:167–171
- safety and accessibility 83:648–649
- supply and distribution
  - ensuring, in Malawi 85:152–155
  - impact of globalization 79:827–833
  - management principles, in Tunisia 77:525–529
  - TRIPS agreement and 82:813, 82:815–821
- use by indigenous communities in Bolivia 82:243–250
- MEDLINE, inclusion of Nepalese journal 83:400
- medroxyprogesterone acetate, depot see depot-medroxyprogesterone acetate
- Meeting the mental health needs of developing countries: NGO innovations in India (Patel & Thara) 81:846
- melarsoprol, for Gambian trypanosomiasis in Republic of Congo 84:783–791
- men
  - behaviour change to improve women's health 85:505–506
  - in brothels, HIV testing in Senegal 80:709–713
  - fertility and reproduction in Gambia 78:570–579
  - risk factors for sexual violence against intimate partners 82:330–337
  - unmarried young, HIV infection patterns and risk behaviours in Viet Nam 85:35–41
- meningitis
  - bacterial, in Niamey, Niger 77:499–508
  - diagnosis and management in Bangladesh 79:1096–1105
  - epidemics in Africa 80:342–349, 80:991
*Haemophilus influenzae* type b (Hib), in Bulgaria 80:690–695

meningococcal see [meningococcal meningitis](#)

meningococcal meningitis (*Neisseria meningitidis* meningitis)

C vaccine, in United Kingdom 83:301–307
in Niamey, Niger 77:499–508
W135 strain in Burkina Faso 81:776, 82:398

mental disorders

Asian tsunami impact 83:405–406
burden
in Australia 79:1076–1084
comparison of methods used to estimate 78:427–438
cross-national comparisons 78:413–426
measurement 78:500, 78:502–504, 78:507–508
persistence 78:446–454
socioeconomic differences in Sweden 83:92–99
economic change and 78:505–506
epidemiology 78:464–474
genetics 78:455–463
Hurricane Katrina impact 84:930–939
interventions 78:411, 78:412
intimate partner violence as cause, in Australia 84:739–744
and poverty, in developing countries 81:609–615
pre-existing, and injury, in Canada 83:345–352
prevention 78:500, 78:501
smoking links 79:79–80
WHO's role in fighting 83:407–408
*World health report 2001* 79:1085, 79:1089

mental health

in 21st century 78:411
mainstreaming 78:412
maternal, in Eritrea 81:360–366
policy development 78:475–482, 78:483–490
priorities in Iraq 82:555
priorities in South Africa 78:508–510
project in Goa, India 85:576
project to foster synergies 81:75
research in developing countries, role of scientific journals 82:226–228
resources, WHO report 80:523
in south-eastern Europe 82:539–546
support in emergency settings 85:822
two new reports 82:810
WHO 2001 campaign events 79:176, 79:487
WHO strategy 78:500–514

mental health care

in Australia 78:510–511
in Cambodia 77:275–277
expanding and strengthening 78:513–514
policy in Kerala, India 77:707
reform in Russian Federation 85:858–866
removing barriers to 78:506–507, 78:511–512
services at primary level 78:501–512
treatment gap 82:858–866
in USA 81:695
users' satisfaction 78:712
in Viet Nam 84:664–668

meta-analysis
residential exposure to radon and lung cancer 81:732–738
see also systematic reviews
methaemoglobinemia, cytochrome-\textit{b}$_5$ reductase activity and 77:749–753
metronidazole, vaginal discharge in West Africa 84:729–738

Mexico
aerosolized \textit{vs} injected measles and measles–rubella vaccines 80:806–812
aetiology of maternal mortality 79:805–810
breastfeeding practices 77:323–330
clinical training unit for child health 77:936–945, 79:434–441
ethics and equity of rationing antiretroviral treatment 83:541–547
health services for poorest people 84:592–593
injury prevention counselling of parents 81:591–598
magnesium sulfate use for pre-eclampsia and eclampsia 85:763–767
mortality data collection 84:166–168
oral health care needs of elderly 83:646–647
oral rehydration therapy 78:1246–1255
poliovirus carrier status in primary immune deficiency disorders 82:3–8
rotavirus vaccine launch 83:167
seasonal diarrhoeal mortality in children 77:375–380

micro-card agglutination test for trypanosomiasis (micro-CATT), evaluation 80:882–886
micro-insurance units 79:672–678
microbicides, topical anti-HIV 82:393–394
microbiological culture, \textit{Streptococcus pneumoniae} in tropics 79:43–47
microbiological quality
drinking-water in Israel 78:1466–1473
wastewater used in agriculture 78:1104–1116
microeconomics, health, nutrition and prosperity 80:106–113
Micronesia, areca nut chewing among schoolchildren 83:656–660
micronutrients
deficiencies 81:79
  global damage assessment 82:230–231
dilution by high dietary sugar 81:599–608
microscopy, for malaria diagnosis 79:933–941

Middle East
adolescent suicide 84:840
effects of violence on health 79:176
middle-income countries see developing countries
midwives
attendance at birth, poor women in Indonesia 85:774–782
audit of maternal mortality in Indonesia 80:228–234
economic analysis of training in Indonesia 80:47–55
home delivery of heat-stable vaccines 77:119–126
management information system for 77:186–189
private, utilization in low- and middle-income countries 81:616–623
see also birth attendants
migration
health and 82:561, 85:200–206
impact on life expectancy in Australia 85:474–481
nurses; trends and policies 82:587–594
patterns of physicians and nurses in 1970s 82:624–625, 82:626–630
strategies to discourage 82:608–615, 82:616–623

military personnel
infectious disease surveillance 85:174–180
Plasmodium vivax malaria prophylaxis in Republic of Korea 84:827–834
Vi polysaccharide typhoid vaccine 79:811–817

milk
products, causing food poisoning 78:1063
substitutes, for infants of HIV-infected mothers 82:164–171

Millennium Development Goals (MDGs)
equity-oriented knowledge translation to meet 84:643–651
equity-sensitive monitoring of maternal and child health 84:519–527
free access to journals and 84:692
Global Fund to Fight AIDS, Tuberculosis and Malaria and 85:805–811
importance of tobacco and alcohol control 83:799
possible impact of health worker shortage 83:5–6
quality improvement in health care and 84:259
quality of tuberculosis control data 85:370–376
responsive parenting: interventions and outcomes 84:991–998
round table debate on achieving 82:947–952
sanitation targets 82:234–235
tracking progress to child mortality targets 84:225–232
tuberculosis control 85:341–347
UN World Summit 83:729
updates on progress 82:156–157, 82:804–806

The Millennium Development Goals for Health: rising to the challenges (World Bank) 83:876–877

miltefosine
availability for treatment of kala-azar, in India 83:394–395
for leishmaniasis 80:688

Mine Ban Treaty 78:1370
mineral deficiencies, global damage assessment 82:230–231
mining project, integrated environmental impact assessment, in Canada 81:434–438
ministries of health, organization 78:1005–1014
Mintzberg, H 78:1005–1014
MMR see measles-mumps-rubella vaccine
molecular entomology, and malaria control 78:1412–1423
molecular epidemiology
infectious diseases 81:474
tuberculosis 80:477–482
Mongolia, livestock vaccination for brucellosis 81:867–876
monkeys
malaria spread to humans 82:392–393
neurovirulence testing of poliovirus vaccine 81:251–260
morbidity
after economic crisis in Republic of Korea 81:567–572
children, effects of malaria chemoprophylaxis 81:205–216
compression of, and active ageing 80:243–250
and hospitalization in Kerala, India 80:746–751
maternal, from direct obstetric causes 78:593–602
pre-existing, and injury, in Canada 83:345–352
prevalence rates 79:1047–1055
Morocco
contracting-out of health services 84:867–875
polio eradication and routine immunization 80:822–828

mortality
causes of see causes of death
climate change and 82:481
economic development and 81:831–832, 81:833–841
gender and literacy and, in Ethiopian adults 80:714–720
ICD coding changes and trends 82:904–913
inequalities in Australia 84:198–203
intrapartum, global estimates 83:409–417
married older adults in Beirut, Lebanon 85:482–486
measuring 84:162, 84:170–171
in China 84:168–169
cluster and systematic sampling methods 84:290–296
letters 84:254–256
malaria 84:165–166
maternal mortality 84:173–180
in Mexico 84:166–168
suicide 84:260
tracking progress towards Millennium Development Goals 84:225–232
non-specific effects of measles vaccination 83:238
patterns in Russian Federation 80:876–881
pesticide-related, in Sri Lanka 81:789–798
prehospital trauma care preventing 84:507
statistics
in China, evaluation 83:618–625
data sources in developing countries 82:83
in Jordan 77:641–650
and public health usefulness, in Cape Town 84:211–217
quality of global 83:171–177
in Thailand, critical assessment 84:233–238
tsunami-related, Aceh Province, Indonesia 85:273–278
in US subpopulations 80:9–15
William Farr's studies 78:86–96
see also child mortality; infant mortality; maternal mortality; perinatal mortality

mortuary statistics, to develop an injury surveillance system 80:357–364
mosquitoes
aircraft disinsection 78:995–1004
control in Latin America 85:737–738
DDT for control 82:472–473
genome sequence 80:918–919
house spraying for malaria control 78:1389–1400, 79:77, 79:687
insecticide-treated nets for controlling see insecticide-treated nets
malathion resistance/carboxylesterase mechanism 79:1060–1064
pyrethroid resistance 77:230–234
spatial targeting of interventions 78:1401–1411
West Nile virus 78:1168
see also Anopheles mosquitoes; Culex quinquefasciatus
mothers
breastfeeding education 77:381–385
hygiene promotion programme 79:518–527
nutritional status in Congo 78:108–118
preventing vertical transmission of HIV see under HIV/AIDS
psychosocial well-being in Eritrea 81:360–366
risk factors for adverse birth outcomes, in Tanzania 85:9–18
vaccination and, in Italy 77:224–229
see also maternal health; maternal mortality
motor vehicle accidents see road traffic accidents
Move for Health Day (10 May) 81:232
Mozambique
burden of disease in 1994 79:546–552
diagnostic accuracy of antenatal screening 84:97–104
flood-related problems 78:562
malaria prevention in pregnancy 85:873–879
respiratory syncytial virus infection 82:914–922
secondary prevention of stroke 82:503–508
training medical assistants for surgery 77:688–691
Multiple-Indicator Cluster Survey (MICS), tetanus toxoid coverage 80:696–703
multiple sclerosis, hepatitis B vaccine and 79:379
mumps
burden of disease 77:3–14
oral fluid for diagnosis and surveillance 80:76–77
vaccine
global review 77:3–14
safety 78:199–204
see also measles-mumps-rubella vaccine
musculoskeletal disorders 81:629
burden of major 81:646–656
improved education for doctors 81:677–683
recent developments and future research 81:686–688
Myanmar
active surveillance for congenital rubella syndrome 84:12–20
efficacy of different antimalarials 77:244–249
funding of tuberculosis, HIV/AIDS and malaria projects 83:724–725
severe malaria and associated deaths 77:310–314
Mycobacterium tuberculosis
infection see tuberculosis
molecular epidemiology 80:477–482
Mycobacterium ulcerans disease 83:785–791
Mycoplasma genitalium, in West Africa 79:118–126
mycotoxins, toxicity 77:754–766
myocardial infarction, WHO-PREMISE study 83:820–828
Nabarro, David, interview 83:90–91
Namibia
  equity in primary health care provision 80:675–681
  hepatitis C in blood donors 77:965–972
National Center for Health Statistics (NCHS), growth reference data 78:535–541
National Control of Diarrhoeal Disease Programme (1980–93), Philippines 80:637–643
National Health Service (NHS), UK 78:845–846
National Institute of Allergy and Infectious Diseases (NIAID), Jordan Report 2000 78:563
National Institute of Mental Health (NIMH) web site 77:861
National Institutes of Health (NIH)
  priority-setting in research funding 77:362–363
PubMed Central see PubMed Central
national public health institutes (NPHI) 83:154–157
Native Americans, hepatitis A 78:948
natural disasters
  in 2005 84:4–6
  El Niño-associated 78:1127–1135
  need for WHO coordinating centre 84:767
see also earthquakes; hurricanes; tsunami
navy laboratories, public health role of US 85:165–166
needles, best infection control practices 81:491–500
neglected diseases
  development and delivery of medicines 85:572
  new organization supporting research on 80:842–843
  stimulating research and development 84:346–348, 84:376–381, 84:414–416
see also orphan drugs; rare diseases
Neisseria meningitidis meningitis see meningococcal meningitis
neonatal deaths
  causes of early, in developing countries 84:699–705
  low-birth-weight infants in Bangladesh 79:608–614
  perspectives 81:224–225
  in rural India 84:706–713
  in rural Pakistan 80:271–276
see also perinatal mortality
neonatal health care see maternal and newborn health services
neonates
  BCG vaccine safety 79:337–343
  birth dose of hepatitis B vaccine in Indonesia 83:456–461
  congenital syphilis management 82:424–430
  conjunctivitis see ophthalmia neonatorum
  hepatitis B vaccination in rural China 85:688–694
  improving care 81:224–225
  improving hepatitis B vaccine coverage 84:65–71
  intrapartum deaths, global estimates 83:409–417
  perceptions of danger signs, in India 84:819–826
  supplementary immunization to prevent tetanus, in Pakistan 82:643–651
  tetanus 80:271–276, 80:696–703
  training for essential care in Brazil 79:1024–1031
  WHO's role in promoting health 83:247–248
Nepal

- anterior chamber intraocular lenses 78:372–378
- awareness of national immunization day programme 77:602–606
- clinical diagnosis of trachoma 77:461–466
- deworming programme in schools 80:423–424
- essential medicines for chronic diseases 85:279–288
- falling child mortality 80:988–989
- financing policies and underutilization of child health services 83:338–344
- law against selling human organs 81:547–548
- medical spending and health outcome 81:844–845
- one-journal-for-MEDLINE initiative 83:400
- public–private partnership to control tuberculosis 82:92–98
- risk factors for early infant mortality 81:717–725
- risk of death following pregnancy 80:887–891

Netherlands

- avian influenza A outbreak 81:471
- burden of injury 85:27–34
- cohort smoking intensity 80:26–32
- epidemiological models 80:622–628
- estimation of burden of depression 83:443–448
- ICD coding changes and cause-specific mortality trends 82:904–913
- knowledge brokering to promote policy-making 84:608–612
- legalization of euthanasia 79:580
- Priority Medicines Project 83:324
- strategies for effective policy on health impact assessment 81:404–407
- Netherlands Health Council, on xenotransplantation 77:79–81
- nets, insecticide-treated see insecticide-treated nets
- neurocysticercosis, as reportable disease 78:399–406
- nevirapine, to prevent mother-to-child transmission of HIV accessibility in South Africa 80:335, 80:521–522
- achievability of targets 79:1138–1144
- district-wide programme in South Africa 83:489–494
- operational effectiveness of South African programme 85:466–473
- regimens 83:483
- in women of unknown serostatus 83:224–229

New England Journal of Medicine 78:862–863

New Zealand, institutionalization of policy-level health impact assessment 83:472–477

Newborn infants see neonates

Newell, Ken 78:144

Nicaragua

- competence of skilled birth attendants 85:783–790
- impact of violence against women on infant and child mortality 81:10–18

Nicholson, Baroness Emma 80:176

Nicotine

- alternative forms of delivery 78:943, 78:944
- removal from tobacco products 78:943, 78:944

Niger

- bacterial meningitis epidemiology 77:499–508
- management of severely ill children at first-level health facilities 81:522–531

Nigeria
assess the assessing of loiasis 80:852–858
complementary food preparation and handling 79:423–433
fight against counterfeit drugs 84:690
health research influencing political manifestos 82:75
integration of mass drug administration programmes 84:673–676
malaria control 78:1389–1400
management information system for nurses/midwives 77:186–189
measuring barriers to condom use 79:926–932
polio vaccine safety 82:313
respiratory syncytial virus infection 82:914–922
resumption of polio immunization 82:633, 82:717
STI management flowchart 79:301–305
tariffs and taxes on insecticide-treated bednets 80:892–899
night blindness
  awareness in southern India 79:96–102
  see also vitamin A; xerophthalmia
nitrates, in drinking water, cytochrome b₅ reductase activity and 77:749–753
3-nitropropionic acid, toxicity 77:754–766
noma, global burden 83:661–669
non-profit organizations, tackling neglected diseases 82:395–396
noncommunicable disease see chronic disease
nongovernmental organizations (NGOs)
  DOTS implementation for tuberculosis control 82:580–586
  health service delivery in Afghanistan 85:712–718
  humanitarian assistance in Rwanda 77:607–609, 77:1020
  immunization provision in Cambodia 82:661–667
  mental health care in Russian Federation 85:858–866
  participation in health research 82:757–763
  STI intervention in Cambodia 83:434–442
tuberculosis control in Democratic Republic of the Congo and 85:642–643
nonsteroidal anti-inflammatory drugs (NSAIDs)
  in osteoarthritis 81:689–690
  reduction of Alzheimer risk 80:79
Nordström, Anders, interview 84:515–84:516
Norplant contraceptive 79:690
North America
  medical education, Flexner report 80:592–593, 80:594–602
  mental disorders 78:413–426
  see also Canada; United States of America
Norway
  burden of injury 85:27–34
  ICD coding changes and cause-specific mortality trends 82:904–913
  nurse migration to 82:587–594
nosocomial bacteria, antimicrobial resistance in Greece 77:595–601
Novartis, free anti-tuberculosis drug supplies 82:79
Nuremberg code 85:573
nurses
  anaesthesia services 77:267–270
  antiretroviral therapy roll-out in Botswana 85:555–560
  brain drain counter strategies 83:84–85
  community-based, reproductive and child health in Ghana 84:949–955
  coping strategies of underpaid 80:581–584
  immunization, peer training in Indonesia 79:150–158
management information system for 77:186–189
migration
  from developing countries 82:595–600
  patterns in 1970s 82:624–625, 82:626–630
  trends and policies 82:587–594
private, utilization in low- and middle-income countries 81:616–623
recruitment by richer countries 79:1171–1172
skill mix 80:575–580
surveillance of disease outbreaks 79:22–27
training strategies for essential newborn care 79:1024–1031
tuberculosis outcomes and training, in South Africa 83:250–259
see also health care workers
nursing insurance scheme, for elderly in Japan 78:710
nutrition
  advocacy, national development 77:407–415
  education, vitamin A deficiency and 77:784
  global approach 80:952–958
  new WHO strategy 79:176
  in oral disease aetiology and prevention 83:694–699
  prosperity and health, microeconomic perspective 80:106–113
toddlers in Kenya 80:292–299
see also breastfeeding; diet; feeding; food; infant feeding; malnutrition
nutritional status
  breastfed infants in Zambia 78:535–541
measuring
  in relation to child mortality 78:1271–1280
see also anthropometric measures
young children and mothers, in Congo 78:108–118
  nutritionists, food safety training 77:172–175
obesity (and overweight)
  childhood 79:82
  control strategy 80:764
diabetes and 79:273
global approach 80:952–958
hoodia-derived drug 81:382
litigation against food industry 81:309–310
national intervention programme in Singapore 79:908–915
and poverty 83:118–126
prizes for weight loss 77:50–53
role of high sugar intake 81:552, 81:599–608
in rural community in Lebanon 81:639–645
and socioeconomic disadvantage, in Australia 84:976–983
and socioeconomic status, in developing countries 82:940–946
surveillance system in Indian industrial populations 84:461–469
trends in prevalence in United States 81:153
using family history to control 79:321–328

*Obesity prevention and public health* (Crawford & Jeffery) 84:334
observational studies, STROBE guidelines 85:867–872
obsessive compulsive disorders (OCD), treatment gap 82:858–866
obstetric complications
  perinatal mortality due to 78:621–627
  severe maternal morbidity and 78:593–602
obstetric services
  assessment, in developing countries 80:721–727
  indicators of need 80:317–324
  organization 77:399–406
  see also *maternal and newborn health services*

obstetrics
  clinical audit of hospital-based 78:614–620
  international variations in management of third stage of labour 81:286–291
  preventive medicine in 78:677–686
  risk factors for perinatal mortality, in rural Kenya 81:561–566
occupational accidents
  in Brazil 77:1008–1016
  chemical, global surveillance 83:928–934
  costs in Lebanon 81:509–516
occupational hazards
  asthma, contribution to global burden 83:548–554
  cancer 78:1158–1159
  lead exposure 78:1068–1077
occupational health, and globalization, in southern Africa 79:863–868
occupational mortality, numerator/denominator bias and inequalities in Australia 84:198–203
ochratoxins, toxicity 77:754–766
ocular trauma 79:214–221
oestrogen replacement therapy, in osteoporosis 81:657–664
*Official health statistics – an unofficial guide* (Kerrison & Macfarlane) 79:578
oflaxacin, for tuberculosis 80:518–519
oil project, health and equity impacts, in Africa 81:420–426, 81:427–433
older people
active ageing 77:299
deaths during heatwave in France 81:773–774
expanding population, in Lebanon 82:219–225
homelessness in Brazil 85:888–889
hypertension 79:490–500
influenza vaccination 77:127–131
mortality among married, in Beirut, Lebanon 85:482–486
oral health care needs 83:646–647
osteoporotic fractures 77:416–422
World Health Day focus 77:293–294
see also ageing

Omi, Shigeru, interview 83:809–810

onchocerciasis (river blindness)

Bayesian predictive model, in Amazonian focus 81:482–490
elimination from West Africa 81:75
global epidemiology 79:214–221
ivermectin mass treatments 80:384–390
mass drug administration programmes in Nigeria 84:673–676
role of bacteria 80:336

Onchocerciasis Control Programme (OCP), completion (December 2002) 81:75
One world: the ethics of globalization (Singer) 81:147

ophthalmia neonatorum

Credé's prophylaxis 79:262–263, 79:264–266
global epidemiology 79:214–221

ophthalmology services

in India 77:104–109
see also eye hospitals

oral cancer

areca nut chewing by schoolchildren and 83:656–660
global burden 83:661–669

oral contraceptives

checklists for community provision 78:1015–1023
for contraception within marriage 82:180–186

oral disease

areca nut chewing-schoolchildren in Micronesia 83:656–660
in developing countries 82:238
diet and nutrition in aetiology and prevention 83:694–699
global burden 83:3, 83:661–669
in HIV infection 83:700–706
prevention and health promotion strategies and approaches 83:711–718

oral fluid samples

diagnosis and surveillance of measles, mumps and rubella 80:76–77
for evaluation of population immunity 79:588–595
see also saliva samples

oral health

-related quality of life (OHRQoL) measure, in oral health service planning 84:36–42
care needs of elderly 83:646–647
general health, quality of life and 83:644
global risk factors 83:661–669
information systems 83:686–693
promotion 83:677–685, 83:711–718
role of FDI World Dental Federation 83:719–720
sociodental approach to assessing children's needs 84:36–42
tobacco use and 83:643
WHO's action for continuous improvement 83:642
oral rehydration therapy (ORT)
cost-effectiveness in developing countries 82:523–531
implementation and effect on mortality 78:1246–1255
prize for discovery 80:991
use in low- and middle-income countries 85:42–48
organ transplantation
international organ trade (transplant tourism) 85:5–6, 85:905
integration of current information 85:955–962
Nepali legislation 81:547–548
WHO resolution 82:715
using animal organs see xenotransplantation
Organisation for Economic Co-operation and Development (OECD)
budgetary constraints 78:751–760
impact of migration on life expectancy comparisons 85:474–481
medicines for neglected and emerging infectious diseases 85:572
Organization of the Islamic Conference (OIC), commitment to eradication of polio 81:918
organizational theory, in "make or buy" decisions 78:779–790
organophosphate poisoning, influence of regulation on deaths, in Sri Lanka 81:789–798
Orphan Drug Act (ODA), United States 83:301–307
orphan drugs
essential 84:686, 84:745–751
European legislation 78:711
stimulating research and development 84:346–348, 84:376–381
osmotic fragility (OF) test, thalassaemia and haemoglobin E screening 82:364–372
osteoarthritis 81:630
burden of disease 81:646–656
inflammation as important component 81:691–693
osteoporosis
burden of disease 81:646–656
exercise interventions for prevention 81:827–830
new approaches to pharmacological treatment 81:657–664
statin treatment 78:144
treatment strategies 77:431–432
Oswaldo Cruz Foundation, Brazil 85:912–913
otitis media, diagnosis and management in Bangladesh 79:1096–1105
outbreaks
consequences of open reporting 78:1358–1367
global control measures 80:179
Internet as intervention tool 78:1281–1282
need for openness in fighting 84:769–770
surveillance using nurses 79:22–27
waterborne enteric disease in Israel 78:1466–1473
outcomes
benchmarks for Africa in 1990s 78:761–769
health expenditure and, in Nepal 81:844–845
overnutrition, global response to 80:952–958
overweight see obesity
oxamnique, efficacy in *Schistosoma mansoni* infection 81:190–196
oxidative stress, in kwashiorkor 81:910–911
oxytocic agents, international variations in use during third stage of labour 81:286–291
PA-824, for tuberculosis 80:518–519

Pacific
  environmental change 78:1148–1155
  HIV/AIDS surge 80:78
  see also Western Pacific

Pakistan
  blood lead levels in children 79:173, 80:769–775
  contracting-out of health services 84:867–875
  cotrimoxazole dose for childhood pneumonia 83:10–19
  decentralized health systems 78:1024–1035
  essential medicines for chronic diseases 85:279–288
  female health workers 84:845–847
  infant mortality 80:271–276, 80:759–760
  lead content of petrol 81:468
  private sector involvement in disease surveillance 84:72–77
  son preference and reproductive behaviour 78:379–388, 78:1373
  supplementary tetanus immunization 82:643–651
  unsafe injections 78:956–963
  Urban Health Project, Karachi 78:565
  water, sanitation and hygiene education for diarrhoea 81:160–165
  Water and Sanitation Extension Programme (WASEP) 80:75

Palestine
  effects of violence on health 79:176
  health situation 80:922

Pan American Health Organization (PAHO) 84:695–697
  diabetes programmes 77:954, 77:981–987
  measles eradication strategy 82:852–857
  restoration of health services in Haiti 82:316–317

Papua New Guinea
  aetiology of child mortality 80:16–25
  breastfeeding in 77:271–274
  information systems for health sector monitoring 80:752–758

Paracelsus 78:1162–1164

paracetamol, efficacy in febrile children 81:367–374
paragonimiasis, case detection in Lao People's Democratic Republic 85:727–731
Paraguay, Chagas disease vector control 77:331–339
parallel imports, TRIPS agreement and 82:815–821
paralysis, acute flaccid (AFP) see acute flaccid paralysis
parasitic diseases
  control in children in Cambodia 82:636
  ivermectin mass treatment 82:563–571
  see also helminthic infections; intestinal nematodes
paratyphoid fever, global burden 82:346–353
Parcell, Geoff, interview 83:727–728
parenting, responsive, interventions and outcomes 84:991–998
parents, injury prevention counselling in Mexico 81:591–598
paromomycin ointment, for cutaneous leishmaniasis in Iran 81:353–359
Partnership for Maternal, Newborn and Child Health 85:577–579
partnerships
global health 85:567–568
public–private see public–private partnerships

patents
biotechnology 84:412–413
clearing house for genetic diagnostics 84:352–359
DNA, public health implications 84:388–392
genomics knowledge and equity 82:385–389
impact on research in developing countries 80:121–125
patients' interests and 84:919
policy and public health, in Japan 84:417–418
pooling, severe acute respiratory syndrome 83:707–710
public health sensitivity of legislation, after TRIPS agreement 85:49–56
role in pharmaceutical R&D 82:784–790
TRIPS agreement see TRIPS agreement
see also intellectual property rights

PATH Falciparum Malaria IC Strip 77:553–559
Pathobiological determinants of atherosclerosis in youth (PBDAY) study 77:250–257

patient satisfaction
perception of health care professionals 77:356–360
psychiatry services 78:712
quality of health care 79:512–517

patients (service users)
acceptance of priority-setting criteria, in Uganda 82:172–179
advocacy, and arthritis 82:115–120
compliance (adherence) see compliance
evaluations, vs WHO measures of achievement 82:106–114
health service utilization see under health services
perception of health care professionals 77:356–360
perspective on osteoporosis 77:433
safety 82:889, 82:892

PCR see polymerase chain reaction

Peeling, Rosanna, interview 84:594–84:595
peer reviewers 79:1
penicillin
maternal syphilis 82:401, 82:433–438
severe pneumonia in HIV-infected children 84:269–275
pentamidine, for sleeping sickness in Republic of Congo 84:777–782

People's Open Access Education Initiative 85:930–934
Periago, Dr Mirta Roses, interview 84:695–84:697

perinatal mortality
complications of childbirth causing 78:621–627
district-based audit in Indonesia 80:228–234
female circumcision and 80:629–632
risk factors in rural Kenya 81:561–566
see also child mortality; infant mortality; neonatal deaths

periodontal disease
in Burkina Faso 83:650–655
global burden 83:3, 83:661–669
periurban community, unsafe injections 78:956–963
permethrin, residual spraying against Triatoma infestans, in Argentina 82:196–205
personnel, health care see health care workers

Perspectives on health and exercise (Mckenna & Riddoch) 81:546
Perspectives on helminthology (Chowdury & Tada) 80:331

Peru
causes of stillbirths and early neonatal deaths 84:699–705
cervical cancer prevention programme 81:73–74
cholera outbreak 78:1358–1367
costs of delivery of routine immunization 82:676–682
district uptake of IMCI strategy 84:792–801
immune response to measles vaccine 79:1038–1046
infant feeding patterns and risks of death and hospitalization 83:418–426
measles outbreak response immunization 77:545–552
military forces for infectious disease surveillance 85:174–180
pooling public views to set health agenda 83:485–486
reproductive tract infections in rural women 82:483–492
training pharmacy workers in STI management 81:806–814
tuberculosis control using DOTS 85:402
tuberculosis treatment programme 81:777

pesticides
deaths from self-poisoning 83:157–158
exposure in Honduras after hurricane Mitch 79:288–295
influence of regulation on acute poisoning deaths, in Sri Lanka 81:789–798
and suicide and suicide attempts 84:260
see also insecticides

petrol
lead content in Pakistan 81:468
leaded, phasing out 80:82, 80:339, 80:768

pharmaceutical industry
AIDS vaccine development 79:721–727
impact of TRIPS agreement in Thailand 79:461–470
perspective on CIPHI report 84:419–420
reducing prices to developing countries 81:72–73, 81:307–308
registration of clinical trials 82:714, 84:429–431
role of patents in R&D 82:784–790
tackling neglected diseases 82:395–396
WHO clinical trials register 84:513–514

pharmaceutical preparations see medicines
pharmacology, clinical, in medical curriculum 77:707
pharmacy workers, training in STI recognition and management 81:806–814

pharyngitis, group A streptococcal 79:528–533

phenobarbital
availability in developing countries 79:344–351
treatment of epilepsy in Mali 80:532–537

philanthropy, sustainable 84:432–433

Philippines
albendazole, ivermectin and/or diethylcarbamazine for *Ascaris* and *Trichuris*
infections 81:35–42
animal and human *Schistosoma japonicum* infection 84:446–452
blood lead levels of children living in rural areas 85:674–680
diagnosis of malaria in remote areas 79:933–941
DOTS implementation 85:399–400
DOTS-Plus 80:497
HIV and hepatitis B and C prevalence in blood donors and overseas work visa
applicants 85:131–137
immunization safety surveillance system 78:1166
knowledge mapping to support knowledge translation 84:637–638
multidrug-resistant tuberculosis 85:392
National Control of Diarrhoeal Disease Programme (1980–93) 80:637–643
oral rehydration therapy 78:1246–1255
tobacco control 81:694
photographs
last days of polio 82:67–70
Phumaphi, Joy, interview 83:247–248
physical activity
diet and body mass index in Iranian children and adolescents 85:19–26
global approach 80:952–958
during leisure and commuting, in China 80:933–938
and mortality 80:425
national intervention programme in Singapore 79:908–915
new global strategy 82:478, 82:556
new Move for Health Day (May 2003) 81:232
osteoporosis prevention 81:827–830
and socioeconomic disadvantage, in Australia 84:976–983
physicians see doctors
pigs, as organ donors 77:57, 77:67–68
plague, outbreak in India 78:1358–1367
planning
business methods, to monitor health budgets 78:1045–1053
decentralized, and policy, in Kenya 84:669–672
health programmes in Africa 80:761
Iraqi health system 81:848–849
oral health service 84:36–42
pandemic influenza, European countries 85:923–929
use of existing data, United Arab Emirates 78:1324–1329
plants, medicinal see medicinal plants
Plasmodium cynomolgi, exo-erythrocytic cycle 78:1445–1449
Plasmodium falciparum
drug resistance 78:407, 78:1477
genome sequence 78:1424–1437, 79:581, 80:918–919
malaria
chloroquine efficacy in Dar es Salaam 77:740–744
confidential enquiry into deaths 77:263–266, 77:1020
cost-effectiveness analysis of therapy 77:235–243
dipstick assay for diagnosis 77:553–559
efficacy of different antimalarial drugs 77:244–249
in vitro sensitivity to artesunate 77:392–398
mortality and morbidity in Africa 77:624–640
severe, and associated deaths, in Myanmar 77:310–314
treatment during pregnancy 78:274
treatment efficacy 80:538–545, 80:704–708
treatment uptake in Gambia 80:790–796
see also malaria
Malarone resistance 81:382–383
progress with new vaccines 81:902–909
tests of chloroquine resistance 77:34–43
**Plasmodium knowlesi**, human cases 82:392–393

**Plasmodium vivax** malaria, re-emergence and chemoprophylaxis in Republic of Korea 84:827–834

Plianbangchang, Samlee, interview 83:893-894

pneumococcus see *Streptococcus pneumoniae*

**Pneumocystis carinii** pneumonia, cotrimoxazole prophylaxis in HIV-exposed infants 82:290–298

pneumonia

childhood case-finding in RESPIRE Guatemala indoor air pollution trial 85:535–544

chest X-ray-confirmed, in Fiji 83:427–433

cotrimoxazole dose in Pakistan 83:10–19

cotrimoxazole prophylaxis in HIV–exposed infants 82:290–298

diagnosis and management in Bangladesh 79:1096–1105

in Gambia 77:144–148


global incidence 82:895–903

neonatal deaths in rural India 84:706–713

severe, antimicrobial therapy in HIV infection 84:269–275

standard case management in developing countries 81:298–300, 81:301–305

standardized chest X-ray diagnosis 83:353–359

ventilator-associated, prevention 84:604–605

see also acute respiratory infections

poisoning

deaths from pesticides, in Sri Lanka 81:789–798

self-, hospital transfer patterns in rural Sri Lanka 84:276–282

policy see health policy; public policy

policy-making

and decentralized planning in Kenya 84:669–672

evidence from systematic reviews 83:480

knowledge brokering to promote evidence-based 84:608–612, 85:420

mental health care in Viet Nam 84:664–668

polio(myelitis)

eradication

in Afghanistan 79:1088

case study 78:285–297

certification process and lessons learned 82:24–30

challenges and solutions 85:487–492

commitment of Islamic states to 81:918

costs and benefits 78:283–284, 78:286–288


in Cuba 77:681–687

current progress 78:286, 79:582, 81:696–697, 84:595

current threats 80:425

economics 82:683–688

end-stage strategies 82:1, 83:160

in Europe 80:688

final stages in China 78:315–320, 79:103–110

major challenges to success 78:292–293

mobilizing and managing human resources 83:268–273


operational feasibility 78:290–292

photographs 82:67–70
progress in India 78:321–329
remaining pocket in India 85:828–829
routine immunizations and 80:822–828
status in 2007 85:7–8
stopping polio vaccination after 78:347–363
technical feasibility 78:288–290
volunteers' contribution 82:2
wars and conflicts and 78:281–282
in West Africa 80:991
in Western Pacific Region 78:1375, 78:1479
HIV infection as risk factor 78:353, 78:361
outbreaks/cases
in Africa 82:394, 82:557, 82:717
in Angola 78:333, 78:339–346
in Bulgaria in 2001 81:476–481
in India in 2000 81:2–9
in unexpected places in 2001 79:81
post-certification era 82:1
cost analysis of immunization policies 82:9–15
fate of global network 85:87–88
framework for evaluating risks of paralytic polio 82:40–46
immunization strategies in developing countries 82:53–58
polio control measures 82:47–52
research needs 80:176
role of routine vaccination 82:31–39
surveillance
after polio eradication 78:361–363
in Australia 79:1169–1170
in Finland 78:298–304
in India 78:321–329
methodology in China 78:315–320
in southern China 79:103–110
vaccination
awareness of national immunization days in Nepal 77:602–606
campaign in India 81:697
campaigns in Africa 82:237–238, 82:890
cessation after polio eradication 78:347–363
children at risk of HIV infection 81:61–70
national immunization days (NIDs) 78:281, 78:305–314
resumption in Nigeria 82:633, 82:717
routine, in post-certification era 82:31–39
strategies in post-certification era 82:53–58
vaccine-associated
current state of knowledge 82:16–23
developing country perspective 82:53–58
in India 80:210–216, 80:917, 80:987
polio vaccines
compatibility of iodine supplements 77:484–491
coverage in African Region 85:449–457
HIV contamination 79:581
inactivated (IPV)
cost analysis 82:9–15
in developing countries 82:53–58
production site containment 82:59–62, 82:63–66
neurovirulence testing using transgenic mice 81:251–260
oral (OPV)
circulating vaccine-derived polioviruses 82:16–23
cost analysis 82:9–15
in developing countries 82:53–58
doubts about efficacy 85:487–492
Sabin 77:194–201
safety, in Nigeria 82:313
SV40 contamination 78:195–198
polioviruses
in bioterrorism/biological warfare 78:354, 78:360
carrier status, primary immune deficiency disorders 82:3–8
circulating vaccine-derived 82:16–23
containment, and global certification 82:59–62, 82:63–66
detection in wastewater 77:973–980
importation and circulation in Bulgaria 81:476–481
laboratory containment 78:353–354, 78:359
post-eradication laboratory containment 80:311–316
recombination with other enteroviruses 78:353, 78:359
reservoirs, detection 78:361–363
type-3 wild, causing outbreak in Angola 78:339–346
vaccine-derived, persistence 78:349–353, 78:358–359
politics
influence of health research in Nigeria 82:75
syphilis during pregnancy 82:417–423
tobacco control 78:913–919
Pollin Prize for Paediatric Research 80:991
pollution see environmental pollution
polymerase chain reaction (PCR)
African trypanosomiasis (sleeping sickness) 77:745–748, 78:119–124
poliovirus detection in wastewater 77:973–980
poor people
access to health care 83:804–805
access to health services in Mexico 84:592–593
burden of tuberculosis in Uganda 81:799–805
catastrophic health expenditure in Burkina Faso 84:21–27
costs of tuberculosis diagnosis in Malawi 85:580–585
failure of IMCI to reach 84:768, 84:792–801
inequalities in maternity care 85:745–754
inequity and unwanted fertility 85:100–107
links between agriculture and health 84:984–990
new ways to finance health care 84:844–845
public–private collaboration aiding tuberculosis case detection 84:752–758
skilled attendance at birth in Indonesia 85:774–782
WHO's contribution to health of 81:473
see also poverty; socioeconomic status
population
control policies 77:767–770, 77:778–779
determinants of disease 79:988–989, 79:990–996
growth estimates 79:484, 79:798
immunity, oral fluid samples for evaluating 79:588–595
mobility, and health 85:200–206
size, estimation in emergencies 83:164
population ageing 79:484
global dependency and dependency ratios and 82:251–258
in Lebanon 82:219–225
Portugal, tobacco smoking by high-school students 77:509–514
post-traumatic stress disorder (PTSD), after acute emergencies and 83:71–76
postmarketing surveillance, vaccines 78:155–162, 82:828–835
postpartum haemorrhage
evidence-based recommendations for prevention 85:322–323
international variations in management of third stage of labour 81:286–291
potatoes, acrylamides in 80:523
poverty
advance price or purchase commitments for treatment of diseases of 83:301–307
applying science to diseases of 85:509–510
child health and 78:1234–1245
cold undernutrition and morbidity and, in India 83:210–216
community health financing schemes 80:143–150
development and 85:734
and disease, integrated approach to fighting 84:151–152, 84:153–158
equity, human rights and health 81:539–545
equity and 78:1–2
equity of health research and 82:740–745
global distribution of risk factors by level of 83:118–126
harmonizing health and socioeconomic information systems for reducing 83:590–596
health inequalities and 78:1–2, 78:3–17, 78:75–85
health sector inequalities and 80:97–105
Healthy Cities approach to urban 81:222–223
in heavily indebted poor countries 80:151–157
impact of health payments in Thailand 85:600–606
indicators, costs, in Tanzania 83:569–577
investing in children's health and 83:777–784
mental disorders and, in developing countries 81:609–615
progress on Millennium Development Goals 82:804–805
protection against catastrophic health expenditure 80:612, 80:613–621
public spending on health care and 78:66–74
transport and land-use policies and, in Delhi 81:444–450
UNICEF report on child 81:919
in urban areas in developing countries 78:1117–1126
Zero Hunger initiative, Brazil 81:229–230
see also poor people; socioeconomic status
Poverty, inequality and health (Leon & Walt) 79:685
praziquantel
efficacy in Schistosoma mansoni infection 81:190–196
mass administration programme in Nigeria 84:673–676
school-based therapy against anaemia 79:695–703
pre-eclampsia, magnesium sulfate use in Mexico and Thailand 85:763–767
pregnancy
anaemia during
in Burkina Faso 77:916–922
diagnosis 77:15–21
antenatal care see antenatal care
avoiding unsafe 79:81–82
as cause of death in girls in developing countries 82:473
complications, maternal mortality in Russian Federation 84:283–289
ectopic, in Guinea 80:365–370
evidence-based health care in Cameroon 83:895–903
intervals see birth intervals
malaria chemoprophylaxis in Mozambique 85:873–879
malaria during
  in India 77:567–572
  rapid assessment, in Kenya 81:316–323
  susceptibility to 78:1370–1371
  treatment 78:274
outcomes
  adverse, in Tanzania 85:9–18
  global estimates 83:409–417
preventing HIV transmission see under HIV/AIDS
seroprevalence data for modelling HIV/AIDS epidemics 79:596–607
syphilis during 82:401
  in AIDS/HIV era 82:431–432
  case studies 82:410–416
  detection and treatment 82:402–409
  diagnostic accuracy of screening in Mozambique 84:97–104
  economic and programmatic aspects 82:402–409
  overview and recommendations 82:424–430
  pathophysiology and treatment 82:433–438
  people, programmes, policies and politics 82:417–423
tobacco smoking and orofacial clefts 82:213–218
trichomoniasis and bacterial vaginosis 85:297–304
  see also antenatal clinics; maternal mortality; mothers; obstetrics; women
prehospital trauma care 84:507
prenatal diagnosis, thalassaemia 79:1006–1013
Preparing for natural birth, CD-ROM (Righard) 78:1170
Prescrire Prize for Medical and Pharmaceutical Books (2003) 81:854
preterm delivery
  causing neonatal deaths in rural India 84:706–713
  causing stillbirths and early neonatal deaths in developing countries 84:699–705
  and interpregnancy intervals, in United Arab Emirates 80:871–875
preventive medicine
  economic value 84:151–152, 84:153–158
  exploiting potential of vector control 83:942–947
  in obstetrics 78:677–686
  prehospital trauma care 84:507
  role of emergency medicine 84:835–839
  Rose's middle road strategy 85:886–887
primary health care 83:322
  accessibility, Bamako Initiative in Burkina Faso 81:532–538
  cardiovascular risk management by non-physician health-care workers 85:432–440
  child health programmes 78:1234–1245
  compliance with IMCI strategy in Sudan 81:708–716
  costs of tuberculosis and HIV control in South Africa 84:528–536
dental, in Burkina Faso 83:650–655
diagnostic algorithm for paediatric HIV infection 81:858–866
epilepsy in rural Gambia 80:378–383
equity in provision, in Namibia 80:675–681
essential data set for health information, in South Africa 83:632–636
health information technology, in developing countries 82:867–874
integrating reproductive health 77:771–777
integration of basic dermatological care, in Mali 83:935–941
management of severely ill children, in sub-Saharan Africa 81:522–531
mental health services 78:501–512
myths and challenges 78:408, 78:861
organization in Lao People's Democratic Republic 84:132–138
patient evaluations, vs WHO performance measures 82:106–114
patients' perception and satisfaction in Trinidad and Tobago 77:356–360
physicians, clinical training unit 77:936–945
private provision, implications for public health 81:292–297
private sector contracts 78:821–829
prognosis of depression 78:439–445
training health workers to use antimicrobials in childhood illness 82:509–515
for under-fives, quality, in Bangladesh 83:260–267
user fees and attendance 79:665–671
see also community-based health care
primates, nonhuman
as organ donors 77:56–57, 77:62
see also monkeys
prion diseases
discovery of marker 81:548–549
see also bovine spongiform encephalopathy; Creutzfeldt–Jakob disease, variant
Priority Medicines Project 83:324
prisons
hepatitis B vaccination 80:569–574
tuberculosis in Russian 84:265–266
privacy, Human Genome Project and 78:1373
private practitioners
combined public practice 77:209, 83:771–776, 84:336
impact on tuberculosis control programmes 80:836–837, 81:148
private sector
contracts for primary health care 78:821–829
disease surveillance in Pakistan 84:72–77
global public partnerships 78:549–561, 78:699–709
human resources and health franchising, in Africa 83:274–279
improving child health outcomes in developing countries and 81:886–895
international comparisons 78:811–820
in low-income countries 80:325–330
to meet public health goals 84:427
production of health care goods and services 78:779–790
promotion of safe motherhood, in low- and middle-income countries 81:616–623
public health implications in developing countries 81:292–297
quality of antenatal care, in Tanzania 81:116–122
research funding in Africa, relevance to burden of disease 83:511–517
response to AIDS epidemic, in Africa 81:131–137
tuberculosis control programmes 84:876–883
WHO collaboration 79:748–754
see also contracting; public–private mix; public–private partnerships
privatization
contracting as a form of 84:910–913
drinking water management, in Germany 81:408–414
prizes for weight loss 77:50–53
The Professor and the madman – a tale of murder, insanity and the making of the Oxford English Dictionary (Winchester) 79:579
PROFILES programme 77:407–415
prolapse, genital, in rural community in Lebanon 81:639–645
prostate cancer, epidemiological models 80:622–628
prostitutes see sex workers
Protecting the future: HIV prevention, care and support among displaced and war-affected populations (Holmes) 83:478
ProTEST Initiative
costs and cost-effectiveness in South Africa 84:528–536
development 80:939–945
psychiatric epidemiology 78:464–474
psychiatric illness see mental disorders
psychogenic illness, mass, after tetanus-diphtheria toxoid vaccination 79:764–770
psychosocial support
in emergency settings 85:822
see also counselling
psychosocial well-being, maternal, in Eritrea 81:360–366
public goods, global see global public goods
public health
in 21st century 77:953
community-based catalyst approach 83:392–394
concepts 77:101
cross-sectoral cooperation 82:322
globalization 79:842–849
health information systems underpinning 83:578–583
human rights in 77:364
implications of asthma 83:548–554
incorporation of ethics 85:504
programmes, applying best practices 84:594–596
strategy, disease eradication as 78:285–297
TRIPS agreement and 79:381, 82:813, 82:815–821
workforce, in England 85:935–940
Public health, ethics, and equity (Anand et al) 83:875–876
Public Health Act 1848 (England and Wales) 83:866–867, 83:868–872
public health education 85:902, 85:903
in England 85:935–940
mapping advanced capacity in Africa 85:914–922
People's Open Access Education Initiative 85:930–934
round table discussion 85:963–970
strengthening 85:163
Welch & Rose's Institute of Hygiene (1915) 85:977–979
public health schools
around the world 85:906–909, 85:910–911
in Brazil 85:908, 85:912–913, 85:968–969
South African National School of Public Health 85:949–954
in Switzerland 85:974–976
public opinion, SV40 in poliovirus vaccines 78:195–198
public policy
alcohol 78:491–499
to counter brain drain 82:608–615
coupling health impact assessment and environmental assessment in Europe
83:472–477
nurse migration 82:587–594
predicting alcohol consumption in India 83:829–836
private health insurance 83:127–134
response to health inequalities 82:482
tobacco control 78:913–919
tobacco industry tactics and 78:867, 78:902–910
women and tobacco 78:891–901
see also foreign policy and health; health policy; policy-making

public sector
dual job holding by health professionals 77:209, 83:771–776, 84:336
lessons from private health care providers 81:292–297
quality of antenatal care, in Tanzania 81:116–122
publications, WHO, BMA Medical Book competition 81:922

public–private mix
aiding tuberculosis case detection in poor and vulnerable 84:752–758
DOTS strategy for tuberculosis control
in four cities 82:580–586
in India 84:437–445, 85:399
see also contracting

public–private partnerships (PPPs) 79:694, 81:235
AIDS vaccine development 79:721–727
Bristol-Myers-Squibb Secure the Future initiative 79:795–796
disease surveillance 81:550
drug and vaccine development 79:728–734
global (GPPPs) 78:549–561, 78:699–709
for hospitals 84:890–896, 85:900
improving immunization equity in Cambodia 82:661–667
local research and development in India 79:742–747
main targets, diversity and future directions 79:713–720
Malarone Donation Programme 80:817–821
neglected infectious diseases 79:735–741
strategy for WHO 79:748–754
tuberculosis control, cost issues 83:78, 83:558–559
tuberculosis control in Nepal 82:92–98

publishers, scientific
censoring of "dangerous" research 81:308–309
providing wider access to health information 81:700
see also journals

PubMed Central (formerly E-biomed) 78:563
Pugwash Conferences on Science and World Affairs 77:149–155
punishment of children, attitudes of young people 79:382–387
pyrethrins, residual spraying against Triatoma infestans, in Argentina 82:196–205
pyrethroid insecticides
Anopheles gambiae resistance 77:230–234
safety 80:257
for treating mosquito nets 81:324–333
pyrimethamine see sulfadoxine–pyrimethamine